PCI Biotech Holding ASA (OSL:PCIB)

Market Cap	51.51M
Revenue (ttm)	6.74M
Net Income (ttm)	-16.42M
Shares Out	37.33M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,653
Average Volume	46,943
Open	1.432
Previous Close	1.400
Day's Range	1.360 - 1.432
52-Week Range	1.100 - 3.500
Beta	1.52
RSI	53.55
Earnings Date	Apr 25, 2025

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 6
• Stock Exchange: Oslo Børs
• Ticker Symbol: PCIB

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.